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of sexually active women have been found to suffer at 
least one episode of Candida vaginitis and 10% of them 
have been reported to have recurrent episodes (Richter 
et al. 2005, Saporiti et al. 2001).
In spite of the fact that there is a limited but growing num-
ber of antimicrobials that can be used to treat mycotic 
infections such as candidiasis (Fleck et al. 2007, Goa & 
Barradell 1993, Graybill 1996, Hsueh et al. 2005, Kauff-
man 1994, Ostrosky-Zeichner et al. 2003, Pfaller et al. 
2005), there is rapid increase in the patronage of herbal 
remedies as an alternative form of therapy in Nigeria, es-
pecially among the low and middle class citizenry (Ogun-
she & Kolajo 2006; Ogunshe et al. 2006; Ogunshe 2007), 
just as the use of traditional herbal remedies is becoming 
increasingly popular all over the world (Kofi-Tsekpo 2004, 
Steenkamp 2003). Since traditional remedies are part of 
the cultural and religious lives of Africans, which may be 
attributed to accessibility, affordability (Steenkamp 2003) 
and ancestral beliefs, several medicinal plants of Africa 
have been investigated for their chemical components, 
and while some of the isolated compounds have been 
shown to possess interesting biological activities, a few 
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Abstract 
Some Nigerian medicinal plants are popular among tra-
ditional producers of phytotherapies in the treatment of 
sexually related infections. For this study we used modi-
fied agar disk, agar spot and agar well-diffusion methods, 
preparations of simulated crude aqueous and ethanolic 
extracts of 11 traditionally used medicinal plants for in vit-
ro antimicrobial activities against seventy five strains of 
Candida species associated with Candida vaginitis and 
37 vaginal Lactobacillus species. Candida pseudotro-
picalis (Castell.) Basgal were minimally inhibited by the 
plant extracts, while the rate of inhibition of other Candida 
strains by the ethanolic extracts of the plants were, Agera-
tum conyzoides L. (44.4 - 66.7%), Anthocleista djalonen-
sis A. Chev. (57.1 - 66.7%), Senna alata (L.) Roxb. (44.4 
- 75.0%) Ficus exasperata Vahl. (44.4 - 62.5%), Gliricidia 
sepium Kunth ex Steud. (64.3%-75.0%) Chromolaena od-
orata (L.) R.M. King & H. Rob.(57.1%-62.5%) and Rau-
wolfia vomitoria Afzel. (62.5%). Apart from Aspilia africana 
(Pers.) C.D. Adams (24.3%) and Ageratum conyzoides L. 
(35.1%), very low in vitro inhibitory activities of between 
5.4% and 16.2% were produced by the medicinal plants 
against the vaginal Lactobacillus species indicating their 
ethnophytotherapeutic safety.
Background
Sexually transmitted diseases (STDs) are a major cause 
of morbidity and mortality in developing countries (Mayaud 
et al. 1995), and a growing list of fungi has been implicat-
ed in sexually transmissible infections (STI) such as vagi-
nal candidiasis. This is one of the most frequent infections 
of the female genital tract with high incidence rates. A vast 
majority of cases are known to be caused by various spe-
cies of Candida (Adad et al. 2001, Armstrong-James 2007; 
Asmundsdottir et al. 2002, Colombo et al. 2006, Fan et al. 
2008, Hospenthal et al. 2004, Jones 1998, Larone 1995, 
Mashburn 2006, Pfaller et al. 2001). Approximately 75% 
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have been found to be active even in controlled clinical 
evaluations. 
The majority of information about herbs is however, based 
on experience from their historical use (Kambizi & Afo-
layan 2001, Vidyasagar & Prashantkumar 2007). It is 
however, necessary that treatment of any infectious dis-
ease should be supported by scientific evidence; there-
fore, this present pilot study tries to provide information on 
the ethnophytotherapeutic use of certain extracts of me-
dicinal plants on pathogenic Candida species implicated 
in STI. This paper reports an antimicrobial study of 11 se-
lected medicinal plants that are common among the Ni-
gerian traditional herbal practitioners, in the preparation 
of herbal remedies for treatment of Candida vaginitis and 
other STIs. 
Methods
Sourcing of information
In order to obtain ethnobotanical information on the use of 
herbal treatments for various male and female reproduc-
tive infections and disorders, twenty six traditional herbal 
practitioners/healers from eight Nigerian states, Lagos, 
Ogun, Oyo, Osun, Ekiti, Kwara, Edo and Delta states were 
informally interviewed, especially during national herbal 
trade fairs. Information on methods of the herbal prepara-
tions, doses, durations and local names of the medicinal 
plants was also obtained.
Medicinal plant materials
Crude aqueous and ethanolic leaf extracts of plant spe-
cies, Aspilia africana (Pers.) C.D. Adams, Newbouldia lae-
vis (P. Beauv.) Seem. ex Bureau, Ficus exasperata Vahl., 
Senna alata (L.) Roxb., Chromolaena odorata (L.) R.M. 
King & H. Rob., Gliricidia sepium Kunth ex Steud., Bixa 
orellana L., Ageratum conyzoides L., Anthocleista djalon-
ensis A. Chev., Kalanchoe pinnata (Lam) pers. (former-
ly Bryophyllum pinnata) and Rauwolfia vomitoria Afzel., 
were screened against the test Candida and Lactobacil-
lus strains. The part of the plant (leaves) used was based 
on the information obtained from traditional practices of 
the Nigerian medicinal plant sellers, traditional practitio-
ners and herbalists. Botanical identification of the plant 
materials was confirmed at the Herbarium of Department 
of Botany and Microbiology, University of Ibadan, Nigeria 
and the plant materials were later deposited there.
Preparation of crude plant extracts 
The simulated preparations of the leaf samples were ac-
cording to the methods for the herbal preparations by the 
traditional herbal practitioners and sellers. The leaves 
were collected, first washed with tap water and then ster-
ile distilled water. One kilogram of each fresh leaf samples 
were crushed in a mortar and the plant fluids were then 
extracted with 0.1 liter of hot, sterile distilled water. The 
plant extracts were then sieved with sterile Whatman filter 
paper. Another set of each plant was macerated and ex-
tracted in 0.1 liter of 95% ethanol for 24 hours. 
Microorganisms 
A total of 54 Candida and 37 Lactobacillus isolates were 
used in this study. The Candida spp. were isolated from 
high vaginal swabs (HVS) and endocervical swabs (ECS) 
of patients at the Special Treatment Centre, University 
College Hospital, (UCH), Ibadan, while the Lactobacillus 
strains were isolated from the human vaginal samples of 
healthy, pre-menopausal women that had not been on an-
timicrobial therapy in about six months prior to the collec-
tion of the specimens.
Culture media and methods
The Lactobacillus spp. were grown on de Man, Rogosa 
and Sharpe (MRS) medium (Lab M, England). The Lacto-
bacillus species from the vaginal specimens from non-dis-
eased subjects were obtained by cutting the swab sticks 
into modified MRS broth at pH 5.3 - 5.5 and incubating 
anaerobically in 5% CO2 (Gas Pak Anaerobic System, Ox-
oid) at 32°- 35°C for 24-48 hours. The broth cultures were 
subsequently streaked unto MRS agar and incubated an-
aerobically in 5% CO2 (Gas Pak Anaerobic System, Ox-
oid) at 32°- 35°C for 24-48 hours. Representatives of each 
different colony type were randomly picked from the pri-
mary plates and sub-cultured by repeated streaking onto 
sterile MRS agar plates to assure purity. The Lactobacil-
lus species were characterized based on standard pheno-
typic taxonomic tools (Antonio et al. 1999). The Lactoba-
cillus strains were kept in triplicates on MRS agar slants 
as bench cultures, while the Lactobacillus stock cultures 
were stored in Hogness freezing medium (3.6mM K2H-
PO4; 1.3mM KH2PO4; 2.0mM Na-citrate; 1.0mM MgSO4; 
12% glycerol) and kept frozen.
The cervical swabs (CS) and high vaginal swabs (HVS) 
of the female patients were streaked directly unto the pre-
poured, sterile modified Sabouraud Dextrose Agar (SDA) 
plates and then incubated aerobically at 30°C for 24-48 
hours to isolate the Candida species. Representatives of 
each different colony type were randomly picked from the 
primary plates and sub-cultured by repeated streaking 
onto sterile SDA agar plates to assure purity. The Candida 
species were characterized based on standard phenotyp-
ic taxonomic tools. The strains were kept in triplicates on 
SDA agar slants as bench and stock cultures and kept at 
4°C.
Antimicrobial bioassay
Each Candida and Lactobacillus strain was suspended in 
SDA and MRS broth respectively and incubated at 30°C 
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and 35°C for 18-24 hours. The crude aqueous and eth-
anolic extracts of the leaves (500µl and 1000 µl) were 
screened against the test Candida spp. and vaginal Lac-
tobacillus spp. and the detection of antagonistic activity 
was determined by the modified agar spot-diffusion, agar 
disc-diffusion and agar well-diffusion methods of Tagg et 
al. (1976).
Agar spot-diffusion method 
Sterile SDA and MRS were separately poured into each 
sets of sterile Petri plates and allowed to set at room tem-
perature after which the agar surfaces were inoculated 
by streaking with 500µl of each Candida and Lactobacil-
lus strain. Plant extracts of 500µl and 1000µl in which 1% 
sterile agar was homogenised to prevent spreading of the 
extracts on the agar surface, were separately spotted (dis-
pensed) into the pre-seeded SDA and MRS agar plates. 
The plates were then incubated un-inverted at 32°C for 
the Candida and 35°C for the Lactobacillus strains for 24-
48 hours. Sterile, distilled water incorporated into ster-
ile soft agar served as control. The experiment was per-
formed in duplicates and the mean of zones of inhibition 
were determined and recorded.
Agar disc-diffusion method
Sterile SDA and MRS were separately poured into each 
sets of sterile Petri plates and allowed to set at room tem-
perature after which the agar surfaces were inoculated 
by separately streaking with 500µl of each Candida and 
Lactobacillus strains. Sterile 6 mm in diameter sterile filter 
paper discs were separately impregnated with 500µl and 
1000 µl of each plant extracts. The impregnated wet discs 
were placed on the pre-seeded agar plates and then in-
cubated un-inverted at 32°C for the Candida and 35°C for 
the Lactobacillus strains for 24-48 hours. Sterile, distilled 
water-impregnated discs were used as control. Zones 
of inhibition were measured and recorded in mm diam-
eter. The experiment was performed in duplicates and the 
mean of zones were determined and recorded.
Agar well-diffusion method
Sterile SDA and MRS were separately poured into sterile 
Petri plates and allowed to set at room temperature, after 
which holes 6mm in diameter were bore into the set agar 
plates. The agar surfaces were flamed with inverted Bun-
sen flame and the agar surfaces inoculated separately by 
streaking with 500µl of each Candida and Lactobacillus 
strains. Plant extracts of 500 µl and 1000 µl was sepa-
rately introduced into the SDA and MRS agar wells. The 
plates were then incubated un-inverted at 32°C for the 
Candida and 35̊C for the Lactobacillus strains for 24-48 
hours. Sterile, distilled water incorporated into sterile soft 
agar served control. The experiment was performed in du-
plicates and the mean number of zones of inhibition were 
determined and recorded.
Results
Among the crude aqueous extracts of the screened me-
dicinal plants, only B. orellana (13.0% inhibition), R. vomi-
toria (3.7% inhibition) and S. alata (1.85% inhibition) ex-
hibited very minimal inhibitory activities against the Can-
dida species, while other plants displayed no inhibition 
against the test Candida strains. The zones of inhibition 
by the aqueous leaf extracts of the plants were between 
15.0 - 25.0 mm. However, results of Tables 1 to 4 indicat-
ed that high inhibitory activities were exhibited against the 
test Candida species by the ethanolic extracts of A. co-
nyzoides, A. djalonensis, S. alata, F. exasperata, B. orel-
lana, G. sepium and C. odorata. 
Candida albicans (C.P. Robin) Berkhout strains were 
highly inhibited by G. sepium (64.3%), S. alata (64.3%) 
and moderately inhibited by A. djalonensis (57.1%), 
C. odorata (57.1%), N. laevis (57.1%) and R. vomitoria 
(57.1%). Among the Candida glabrata (H.W. Anderson) 
S.A. Mey. & Yarrow strains, very high inhibitory activities 
were exhibited by S. alata (75.0%), G. sepium (75.0%), A. 
conyzoides (62.5%), A. djalonensis (62.5%), C. odorata 
(62.5%), F. exasperata (62.5%) and R. vomitoria (62.5%). 
Candida tropicalis strains were also highly inhibited by A. 
conyzoides (66.7%), A. djalonensis (66.7%) and F. exas-
perata (53.3%) while minimally inhibited by A. conyzoides 
(44.4%), F. exasperata (44.4%) and S. alata (44.4%). 
None of the strains of C. pseudotropicalis was inhibited by 
the crude ethanolic extracts of C. odorata and K. pinnata 
but very minimal to moderate inhibitory activities (11.1 – 
44.4%) were exhibited by the other crude ethanolic plant 
extracts.
With the exception of A. africana (24.3%) and A. co-
nyzoides (35.1%), very low in vitro inhibitory activities be-
tween 5.4% and 16.2% were displayed by the medicinal 
plants against the vaginal Lactobacillus species (Table 
5). 
Discussion
Sexually transmissible Infections (STIs) are currently gain-
ing significant importance due to rapid spread of the dis-
eases, high cost of treatment and increased risk of trans-
mission of other STDs. Meanwhile, vulvovaginal candidi-
asis has also been reported to be a common cause of 
vaginitis (Hildago 2006, Spinillo 1992). Several species of 
Candida have been implicated in vulvovaginal candidia-
sis, which has been and continues to be a major feminine 
disease. The Candida strains which were assayed for in 
this study were C. albicans (25.9%); C. glabrata (28.9%); 
C. pseudotropicalis (16.7%) and Candida tropicalis (Cas-
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S/N Laboratory 
codes of Candida 
glabrata strains
Ager Fic Anth Chrom Senna Gliric Kalan Bixa Rauv Newb Aspil
1 C. glabrata BC2 15.01 18.01 20.01 R R 16.01 R 16.01 35.02 R R
2 C. glabrata HC R R 20.01 15.01 30.02 R R R R R 15.01
3 C. glabrata 1C2 20.01 35.02 28.02 35.02 30.02 30.02 35.02 35.02 30.02 30.01 35.02
4 C. glabrata 1TC R R 30.02 R 21.01 R R R 12.0 R R
5 C. glabrata X1C 20.01 30.02 R 30.02 25.02 30.02 R 30.02 R R R
6 C. glabrata CA3 R R 15.01 R 14.0 R R R 17.01 R R
7 C. glabrata CA6 10.0 15.01 20.01 R 15.01 R R R 25.02 R 35.02
8 C. glabrata CA10 R R R R R R R 20.01 R R R
9 C. glabrata CA12 24.01 28.02 R R 10.0 R R 30.02 R 18.01 R
10 C. glabrata CA27 25.02 28.02 20.01 R 15.01 R R R 17.01 R R
11 C. glabrata CA34  28.02 30.02 R R R R R R R R R
12 C. glabrata CA36   25.02 35.02 12.0 R R R R R R R R
Table 2. In vitro inhibition of Candida glabrata strains by 500µl and 1000µl crude ethanolic extracts of 11 traditional 
Nigerian medicinal plantsusing modified agar spot-diffusion, well-diffusion and agar disk-diffusion methods. Keys: Fic 
= Ficus exasperata; Ager = Ageratum conyzoides; Chro = Chromolaera odonata; Anth = Anthocleista djalonesis; Gliri 
= Gliricida sepium; Senn = Senna alata; Bixa = Bixa orellana; Kalan = Kalanchoe pinnata; Newb = Newbouldia levis; 
Rouv = Rauvolfia vomitoria; Aspi = Aspilia africana. Low susceptibility = 10.0 - ≤14.0 mm diameter zone of inhibition; 
1moderate susceptibility (15.0 – 24.0 mm diameter zone of inhibition); 2high susceptibility (25.0 – ≥35.0 mm diameter 
zone of inhibition). R = resistant (no zones of inhibition or ≤10.0 mm diameter zone of inhibition). R = no zones of 
inhibition or ≤10.0 mm diameter zone of inhibition.
S/N Laboratory 
codes of C. 
albicans strains
Ager Fic Anth Chrom Senna Gliric Kalan Bixa Rauv Newb Aspil
1 C. albicans AC1 15.01 R 15.01 28.02 15.01 16.01 R 18.01 R 25.02 17.01
2 C. albicans AC2 R 22.01 16.01 R 25.02 15.01 15.01 20.01 18.01 R R
3 C. albicans BC1 R R R R 30.02 18.01 R 12.0 R R R
4 C. albicans FC1 R R R R R R R R R R R
5 C. albicans FC2 R R R R R R R R R R R
6 C. albicans GC1 R R R R R R R R 15.01 R R
7 C. albicans GC2 24.01 28.02 15.01 R 17.01 28.02 23.01 28.02 20.01 25.02 R
8 C. albicans 1C1 28.02 28.0** 32.02 26.02 32.02 30.02 32.02 30.0** 32.02 30.02 32.02
9 C. albicans 4C2 R R 30.02 R 30.02 R R R 30.02 R 30.02
10 C. albicans CA2 R R 20.01 R R R R R 15.01 R 20.02
11 C. albicans CA13 R 23.0* R R R R R R R 20.01 R
12 C. albicans CA23 23.01 R R R 20.01 R 30.02 R 30.01 R R
14 C. albicans CA29 25.02 35.02 17.01 R 15.01 R R R R R R
15 C. albicans CA51 R 12.0 18.01 R 15.01 R R R 15.01 10.0 R
Number of susceptibility 5 5 8 2 9 5 4 5 8 5 4
% susceptibility 35.7 35.7 57.1 14.2 64.2 35.7 28.5 35.7 57.1 35.7 28.5
Table 1. In vitro inhibition of Candida albicans strains by 500µl and 1000µl crude ethanolic extracts of 11 traditional 
Nigerian medicinal plants using modified agar spot-diffusion, well-diffusion and agar disk-diffusion methods. Keys: Fic 
= Ficus exasperata; Ager = Ageratum conyzoides; Chro = Chromolaera odonata; Anth = Anthocleista djalonesis; Gliri 
= Gliricida sepium; Senn = Senna alata; Bixa = Bixa orellana; Kalan = Kalanchoe pinnata; Newb = Newbouldia levis; 
Rouv = Rauvolfia vomitoria; Aspi = Aspilia africana. Low susceptibility = 10.0 - ≤14.0 mm diameter zone of inhibition; 
1moderate susceptibility (15.0 – 24.0 mm diameter zone of inhibition); 2high susceptibility (25.0 – ≥35.0 mm diameter 
zone of inhibition). R = no zones of inhibition or ≤10.0 mm diameter zone of inhibition.
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tell.) Berkhout (27.8%). Similar Candida species had ear-
lier been obtained from vaginal samples in cases of vagi-
nitis (Buscemi et al. 2004, Konje et al. 1991, Saporiti et al. 
2001, Verghese et al. 2001, Vráblik et al. 2007).
Some previous studies on antifungal drugs indicated that 
most of the antimycotic drugs have one or more limitations, 
such as profound side effects, a narrow antifungal spec-
trum, poor penetration of certain tissues, development of 
resistance (Bastert 2001, Kauffman 1994), as well as tox-
icity. Therefore, new approaches to the design of novel 
drugs seem to be necessary, more so, since many pa-
tients of STIs are seeking help from alternative systems of 
medicines (Vermani & Garg 2002). The use of traditional 
medicine was also observed to be widespread (Ogunshe 
et al. 2006, Ogunshe 2007) and prevalent over orthodox 
medicine in many parts of Nigeria (Igoli et al. 2004) due to 
several problems associated with the primary health care 
delivery systems in the country, as well as the increased 
S/N Laboratory 
codes of Candida 
glabrata strains
Ager Fic Anth Chrom Senna Gliric Kalan Bixa Rauv Newb Aspil
13 C. glabrata CA42  R 35.02 R R 19.01 R R R 25.02 R R
14 C. glabrata CA43  32.02 25.02 R R 20.01 R R R 28.02 R R
15 C. glabrata CA44  R R 15.01 R 25.02 R 20.01 R 32.02 R R
16 C. glabrata CA61 35.02 R 30.02 R 30.02 R 20.01 R 35.02 R R
Number of susceptibility 10 10 10 3 12 3 3 5 10 2 3
% susceptibility 62.5 62.5 62.5 18.8 75.0 75.0 18.8 31.2 62.5 12.5 18.8
S/N Laboratory 
codes of 
C. tropicalis 
strains
Ager Fic Anth Chrom Senna Gliric Kalan Bixa Rauv Newb Aspil
1 C. tropicalis 2TC R 25.02 R 10.0 R R R R R 20.01 R
2 C. tropicalis 4C1 R 15.01 20.01 R R 18.01 R R 25.02 20.01 20.01
3 C. tropicalis 6C 21.01 18.01 18.01 R 15.01 14.0 R R R 20.01 10.0
4 C. tropicalis 6C1 10.0 R 10.0 30.02 20.01 R R 25.02 18.01 22.0* 18.01
5 C. tropicalis 10C 20.01 R 20.01 R 30.02 R R 20.01 15.01 R 20.01
6 C. tropicalis CA4 35.02 R 20.01 R 14.0 R R R R R R
7 C. tropicalis CA8 35.02 R 23.01 R 30.02 R 15.01 20.01 35.02 R R
8 C. tropicalis CA9 R R R R R R R R R R R
9 C. tropicalis CA14 24.01 24.01 20.01 R 30.02 R R R R R R
10 C. tropicalis CA20 25.02 25.02 R R R R R R R R R
11 C. tropicalis CA26 24.01 28.02 20.01 R 15.02 R R R 17.01 R R
12 C. tropicalis CA28 32.02 30.02 R R R R R R R R R
13 C. tropicalis CA31  R 30.02 23.01 R R R R R 25.02 R R
14 C. tropicalis CA52 20.01 R 28.02 R 20.01 R 23.01 R 35.02 R R
15 C. tropicalis CA53 R R R R 20.01 R R R R R R
Number of susceptibility 10 8 10 2 9 2 2 3 7 4 4
% susceptibility 66.7 53.3 66.7 13.3 60.0 13.3 13.3 20.0 46.7 26.7 26.7
Table 3. In vitro inhibition of Candida tropicalis strains by 500µl and 1000µl crude ethanolic extracts of 11 traditional 
Nigerian medicinal plants using modified agar spot-diffusion, well-diffusion and agar disk-diffusion methods. Keys: Fic 
= Ficus exasperata; Ager = Ageratum conyzoides; Chro = Chromolaera odonata; Anth = Anthocleista djalonesis; Gliri 
= Gliricida sepium; Senn = Senna alata; Bixa = Bixa orellana; Kalan = Kalanchoe pinnata; Newb = Newbouldia levis; 
Rouv = Rauvolfia vomitoria; Aspi = Aspilia africana. Low susceptibility = 10.0 - ≤14.0 mm diameter zone of inhibition; 
1moderate susceptibility (15.0 – 24.0 mm diameter zone of inhibition); 2high susceptibility (25.0 – ≥35.0 mm diameter 
zone of inhibition). R = resistant (no zones of inhibition or ≤10.0 mm diameter zone of inhibition). R = no zones of 
inhibition or ≤10.0 mm diameter zone of inhibition.
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             % Antifungal susceptibility profiles
Pathogens      MYCT MYCC CNSTT CNSTC FLMD TRDX INTZ MYCS FLGY
Candida albicans       92.3       88.4        88.4        88.4       96.1        88.4      96.1       100.0     84.6
Candida glabrata 33.3            33.3            27.8             5.6               - 11.1          33.3            38.9            5.6        
Candida tropicalis  33.3           33.3            27.8             5.6               - 11.1         33.3            38.9            5.6        
Candida pseudotropicalis  27.5          30.0             27.5              - 2.5              2.5          25.0             20.0          10.0          
Table 5. In vitro antifungal susceptibility profiles of Candida species implicated in sexually transmissible infections using 
antifungal agents. Keys:  CNSTT = canesten tablet; CNSTC = canesten cream; = FLGY = flagyl; MYCS = mycostatine; 
INTZ = interzol; FLMD = flucamed; MYCT = mycoten tablet; MYCC = mycoten cream; TRDX = tetradox.
S/N Laboratory codes of 
C. pseudotropicalis
strains
Ager Fic Anth Chrom Senna Gliri Kalan Bixa Rouv Newb Aspi
1 C. pseudotropicalis 2C1 R R R R R R R R R R R
2 C. pseudotropicalis 2C2 R R 20.01 R 25.02 R R 25.02 R R R
3 C. pseudotropicalis 6C2 R R R R R R R R R R R
4 C. pseudotropicalis 9C R 20.01 20.01 R R 12.0 R R R 20.01 20.01
5 C. pseudotropicalis X7C 19.01 24.01 R R R 22.0* R 16.01 R R R
6 C. pseudotropicalis CA16 25.02 23.01 R R 15.01 R R R R R 20.01
7 C. pseudotropicalis CA25 23.01 23.01 R R R R R R R R R
8 C. pseudotropicalis CA48 R R R R 12.0 R R 15.01 R R R
9 C. pseudotropicalis CA65 20.01 R 25.02 R 12.0 R R R 10.0 R R
Number of susceptibility 4 4 3 0 4 2 0 3 1 1 2
% susceptibility 44.4 44.4 33.3 0.0 44.4 22.2 0.0 33.3 11.1 11.1 22.2
Table 4. In vitro inhibition of Candida pseudotropicalis strains by 500µl and 1000µl crude ethanolic extracts of 11 
traditional Nigerian medicinal plants using modified agar spot-diffusion, well-diffusion and agar disk-diffusion methods. 
Keys: Fic = Ficus exasperata; Ager = Ageratum conyzoides; Chro = Chromolaera odonata; Anth = Anthocleista 
djalonesis; Gliri = Gliricida sepium; Senn = Senna alata; Bixa = Bixa orellana; Kalan = Kalanchoe pinnata; Newb = 
Newbouldia levis; Rouv = Rauvolfia vomitoria; Aspi = Aspilia africana. Low susceptibility = 10.0 - ≤14.0 mm diameter 
zone of inhibition; 1moderate susceptibility (15.0 – 24.0 mm diameter zone of inhibition); 2high susceptibility (25.0 – 
≥35.0 mm diameter zone of inhibition). R = no zones of inhibition or ≤10.0 mm diameter zone of inhibition.
beliefs in the potency of the herbal remedies due to se-
ries of classical advertisements by the various traditional 
herbal practitioners (Ogunshe 2007).
Phytotherapeutic studies on candidal vaginitis in Nigeria 
has been less studied and therefore, very limited docu-
mented information (Buwa & van Staden 2006) is avail-
able on the use of certain extracts of medicinal plants on 
pathogenic Candida species associated with sexually 
transmissible infections. However, information from the 
herbal practitioners, medicinal plant sellers and the local 
populace indicated the use of some plants for the treat-
ment of vaginal infections in Nigeria. It was observed in 
this study that F. exasperata, A. conyzoides, A. djalon-
ensis, S. alata and R. vomitoria exhibited the most pro-
nounced inhibitory activities against the Candida species 
in vitro. The findings of this present study also indicated 
that the ethanolic crude extracts of the plants were more 
inhibitory towards the candida species than the aqueous 
extracts.
Ageratum conyzoides L., Asteraceae, is an annual her-
baceous plant (Menut et al. 1993, Ming 1999) of valuable 
agricultural resources and a long history of traditional me-
dicinal uses in several countries of the world. It is widely 
utilized in folk/traditional medicinal practices and pharma-
cological studies by various cultures in Central Africa (Du-
rodola 1977), traditional communities in India (Borthakur 
& Baruah 1987), and in Asia, South America, and Africa 
(Almagboul et al. 1985), although uses vary by regions. It 
was also reported by Lans (2007) that the plant is useful in 
the treatment of prostrate problems and venereal diseas-
es. The results obtained in this study therefore, confirmed 
that A. conyzoides has strong in vitro anti-candidal activi-
ties against Candida strains implicated in sexually trans-
missible infection.
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Table 6. In vitro inhibition of vaginal Lactobacillus strains by 500µl and 1000µl crude ethanolic extracts of 11 traditional 
Nigerian medicinal plants using modified agar spot-diffusion, well-diffusion and agar disk-diffusion methods. Keys: Fic 
= Ficus exasperata; Ager = Ageratum conyzoides; Chro = Chromolaera odonata; Anth = Anthocleista djalonesis; Gliri 
= Gliricida sepium; Senn = Senna alata; Bixa = Bixa orellana; Kalan = Kalanchoe pinnata; Newb = Newbouldia levis; 
Rouv = Rauvolfia vomitoria; Aspi = Aspilia africana. Low susceptibility = 10.0 - ≤14.0 mm diameter zone of inhibition; 
1moderate susceptibility (15.0 – 24.0 mm diameter zone of inhibition); 2high susceptibility (25.0 – ≥35.0 mm diameter 
zone of inhibition). R = no zones of inhibition or ≤10.0 mm diameter zone of inhibition.
S/N Laboratory codes of 
Lactobacillus strains
Fic Ager Chrom Anth Gliric Senna Bixa Kalan Newb Rauv Aspil
1 L. casei VL R R R R R R 28.02 R R R R
2 L. plantarum VL2 R R R R R R R 25.02 R R 35.02
3 L. delbrueckii VL3 R 22.01 R R R R R R R R R
4 L. brevis VL5 R 27.02 R R R R R R R R R
5 L. fermentum VL6 R 12.0 R 35.02 R R R R 10.0 10.0 R
6 L. plantarum VL7 R R R R R R R R R R R
7 L. fermentum VL9 R R R R R R R R R 30.02 20.01
8 L. acidophilus V12 R R R 25.02 R 20.01 R R R R 25.02
9 L. casei VL122 R R R 28.02 R R R R R R 28.02
10 L. fermentum VL13 R R R R R R R R R R 30.02
11 L. acidophilus VLX4 R 28.02 R R R R R R R R R
12 L. casei VL15 R 25.02 R R R R R R R R 30.02
13 L. fermentum VL16 R 10.0 R R R R R R R R R
14 L. acidophilus VL18 R 25.02 R R R R R R R R 20.01
15 L. acidophilus VL18 R 30.02 R R R R R 25.02 R R R
16 L. fermentum VL20 R 30.02 R R R R R R R R R
17 L. fermentum VL20 R R R R R R R R R R 35.02
18 L. plantarum VL21 R 20.01 R R R 20.01 20.01 20.01 R 20.01 R
19 L. fermentum VL22 R R R R R R R R R R R
20 L. acidophilus VL222 R 20.01 R R R R 20.01 20.01 R R R
21 L. reuteri VL23 R 30.02 R R R R 30.02 30.02 18.01 18.01 R
22 L. reuteri VL225 R R R R R R R R 20.01 20.01 R
23 L. acidophilus VL27 R R R R R R R R R R R
24 L. casei VL28 R R R R R R R R R R 20.01
25 L. reuteri VL29 R R R R R R R R R R R
26 L. reuteri VL30 R R R R R R R R R R R
27 L. casei VL32 R R R R R R R R R R R
28 L. casei VL34 R R R R R R R R R R R
29 L. acidophilus VL35 R R R R R R R R R R R
30 L. plantarum VL36 R R R R R R R R R R R
31 L. acidophilus VL54 R R R R R R R R R R R
32 L. casei VL562  R R R R R R R R R R R
33 L. casei VL59  R R R R R R R R R R R
34 L. plantarum VLB   R R R R R R R R R R R
35 L. plantarum VLF  R R R R R R R R R R R
36 L. casei VLH  R 22.01 R R R R R 28.02 R R R
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Similarly, S. alata (L.) Roxb. (syn. Cassia alata) leaves 
have been selected and recommended for the treatment 
of dermatomycotic infections (Phongpaichit et al. 2004, 
Thirach et al. 2003, Wuthi-udomlert et al. 2003; ). Crude 
ethanolic and water extracts of leaves and barks from the 
plant were tested in vitro against Aspergillus fumigatus 
Fresen. and Microsporum canis E. Bodin ex Guég, C. al-
bicans, Staphylococcus aureus and Escherichia coli by 
Somchit et al. (2003). The extracts were also reported to 
be traditionally used in Ivory Coast, West Africa to treat 
bacterial infections caused by E. coli and fungal infections 
caused by C. albicans and some dermatophytes (Crock-
ett et al 1992). It was also observed in this study that the 
inhibitory effects of ethanolic leaf extracts of F. exaspera-
ta, A. conyzoides, A. djalonesis, S. alata and R.vomitoria 
plants were comparable with those of standard antifun-
gals.
There is a classic view that the vagina of healthy women 
is colonized by a homogeneous population of Lactobacilli 
(Balow et al. 1990) and the predominance of Lactobacil-
lus species present in the vagina has been found to confer 
protective activities against urinary tract infections. For ex-
ample, adherence of Lactobacillus acidophilus to the vagi-
nal cell wall has been known to block the attachment of 
uropathogenic bacteria to the surface of the uroepithelial 
cells. The prevention and control of infections by Lactoba-
cillus species is due to the production of some metabolites 
such as bacteriocins, aminoglycosides, hydrogen perox-
ide, diacetyl, and lactic acid, which act as an inhibitory 
barriers against some pathogenic microorganisms (Boris 
and Barbés 2000, Falagas et al. 2006).
Most of the previous ethnobotanical/ethnomedicinal stud-
ies usually considered the antimicrobial activities of me-
dicinal plants on pathogenic flora without considering the 
effect of the medicinal plants on other microflora that in-
habit the same ecological niche where the plants may be 
effective in vivo. Combining the strong in vitro inhibitory 
activities of the selected medicinal plants on the Candida 
strains, and the less inhibitory activities of the plant ex-
tracts on the vaginal Lactobacillus strains, it can be de-
duced that A. djalonensis, R. vomitoria, F. exasperata and 
S. alata are the best potentials in the ethnophytothera-
peutic treatment of STI caused by pathogenic Candida 
strains. 
Collaborative or multidisciplinary studies would assist in 
this recently noted area of concern, so that, while potent 
medicinal plants are curing some infections, they are not 
creating certain conditions for opportunistic infections. For 
example, if the vaginal Lactobacilli are eliminated by any 
of the medicinal plants during phytotherapy, the candidal 
flora would be on the increase, thereby creating an en-
abling environment for the proliferation of opportunistic 
Candida in the vagina and other urogenital pathogenic 
bacterial strains, which can ultimately lead to vaginal can-
didasis and bacterial vaginitis.
Conclusions
Historical attachments to indigenous therapy in Nigeria 
cannot be overlooked, and this is an additional reason for 
the increase in the higher patronage of traditional (phy-
totherapy) in the country. A good understanding of peo-
ples’ choice of ethnophytotherapy would therefore, sup-
port insight into the need for research-based studies on 
medicinal plants that are very popular among different na-
tions. Scientific support based on research findings pend-
ing clinical trials on which plants are effective is therefore 
compulsory, since many Nigerians still depend largely on 
medicinal plants as complementary or alternative form of 
therapy in diseased conditions. This study concludes that 
simulated ethanolic preparations of A. djalonesis, R. vom-
itoria, F. exasperata and S. alata had very minimal inhibi-
tory effects on the vaginal Lactobacillus species, indicat-
ing their ethnophytotherapeutic safety.
Further studies are in progress to determine the compara-
tive inhibitory effects of the traditional simulated and labo-
ratory extraction methods of the plants on the Candida 
species and some other clinical pathogens implicated in 
STI infections. This nature of research study will aid in 
preserving the indigenous knowledge of ethnobotany in 
relation to scientific findings, so as to improve the human 
public health importance, especially from the phytothera-
peutic point of view.
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